Stenocare Updates on Future Supply of Medical Cannabis Products
Stenocare A/S provides an update on the future supply situation for medical cannabis products in Denmark. Regulatory developments in the Netherlands are impacting the availability of Bedrocan products.
Danish medical cannabis company Stenocare A/S issued an update on October 2, 2026, regarding the future supply of its medical cannabis products in Denmark. The update specifically addresses the CannGros product portfolio, which is supplied by Stenocare and originates from Bedrocan in the Netherlands.
The situation arises from recent regulatory changes within the Dutch medical cannabis framework. These changes could affect the availability of Bedrocan's products, potentially impacting Stenocare's supply chain to the Danish market. The company is working to ensure continuity of supply for its patients amidst these regulatory shifts.
Stenocare has previously introduced several of Bedrocan's medical cannabis products to the Danish market. These products are intended for patients for whom standard treatments have proven insufficient. The company emphasizes its commitment to providing high-quality medical cannabis for therapeutic use.
Stenocare A/S is listed on the NASDAQ First North Growth Market in Denmark. The information was published in accordance with the EU Market Abuse Regulation.